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Since April 2012, there have been 17 laboratory-confirmed human cases of respiratory disease associated with newly recognized
human betacoronavirus lineage C virus EMC (HCoV-EMC), and 7 of themwere fatal. The transmissibility and pathogenesis of
HCoV-EMC remain poorly understood, and elucidating its cellular tropism in human respiratory tissues will provide mechanis-
tic insights into the key cellular targets for virus propagation and spread. We utilized ex vivo cultures of human bronchial and
lung tissue specimens to investigate the tissue tropism and virus replication kinetics following experimental infection with
HCoV-EMC compared with those following infection with human coronavirus 229E (HCoV-229E) and severe acute respiratory
syndrome coronavirus (SARS-CoV). The innate immune responses elicited by HCoV-EMCwere also investigated. HCoV-EMC
productively replicated in human bronchial and lung ex vivo organ cultures. While SARS-CoV productively replicated in lung
tissue, replication in human bronchial tissue was limited. Immunohistochemistry revealed that HCoV-EMC infected nonciliated
bronchial epithelium, bronchiolar epithelial cells, alveolar epithelial cells, and endothelial cells. Transmission electronmicros-
copy showed virions within the cytoplasm of bronchial epithelial cells and budding virions from alveolar epithelial cells (type II).
In contrast, there was minimal HCoV-229E infection in these tissues. HCoV-EMC failed to elicit strong type I or III interferon
(IFN) or proinflammatory innate immune responses in ex vivo respiratory tissue cultures. Treatment of human lung tissue ex
vivo organ cultures with type I IFNs (alpha and beta IFNs) at 1 h postinfection reduced the replication of HCoV-EMC, suggesting
a potential therapeutic use of IFNs for treatment of human infection.
Coronavirus (CoV) infections in humans are generally mildand self-limited.Until the outbreak of severe acute respiratory
syndrome (SARS) caused by severe acute respiratory syndrome
coronavirus (SARS-CoV) in 2003, there was limited research on
the tissue tropism and host response following human infection
with coronaviruses. In comparison to human betacoronavirus
229E (HCoV-229E), SARS-CoV was found to be deficient at elic-
iting beta interferon (IFN-) innate immune responses in pri-
mary human macrophages and dendritic cells (1, 2) since SARS-
CoV encodes several antagonists of innate immune-sensing and
signaling pathways (3, 4). The tropism of SARS-CoV in the respi-
ratory tract was primarily restricted to differentiated human air-
way epithelium (5) and alveolar type II pneumocytes (6–8), with
limited tropism for alveolar type I pneumocytes (9).
In 2012, a novel coronavirus was detected in two patients from
Saudi Arabia and Qatar (10, 11). Thereafter, more cases were
identified both prospectively and retrospectively in Saudi Arabia,
Qatar, Jordan, and the United Kingdom, and as of February 2013,
a total of 13 laboratory-confirmed cases and seven deaths have
been reported (12). The apparent severity of this novel coronavi-
rus contrasts with those seen for other human coronaviruses
(HCoVs), with the exception of SARS-CoV (10, 13). The first
reported case, which was fatal, occurred in June 2012 in a 60-year-
old man in Saudi Arabia (11); the second reported case occurred
in a 49-year-oldQatarimanwhowas treated and discharged in the
United Kingdom. From early case descriptions, it appeared that
pneumonia leading to acute respiratory distress syndrome is the
primary manifestation of the disease, but renal dysfunction was
also observed in some cases. The WHO has provided a working
case definition of the disease (12). The disease appears to have an
incubation period of up to 10 days and is not easily transmitted
between humans. The retrospective investigation of an outbreak
of severe respiratory illness in Zarqa, Jordan, in April 2012 (14)
confirmed that at least some of these cases were also caused by
human betacoronavirus lineage C virus EMC (HCoV-EMC). Of
the 13 cases confirmed to date, some have given a history of con-
tact with animals (e.g., camels and sheep) (13), and a zoonotic
origin of the infection is considered likely.More recently, an index
case who acquired infection in the Middle East transmitted infec-
tion to two family contacts in theUnitedKingdom (15), providing
evidence for limited human-to-human transmission, thereby
raising the level of public health concern.
The virus isolate from the Saudi patient has been fully se-
quenced, and the sequencing identifies the virus as a novel human
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virus within betacoronavirus lineage C. Phylogenetically, it clus-
ters in the same group as viruses isolated from Pipistrellus (Pipis-
trellus pipi/VM314/2008/NLD, bat CoV [BtCoV]/355A/2005,
BtCoV/A434/2005, HKU4) and Tylonycteris (BtCoV/133/2005,
HKU-5) bats in Hong Kong/China and the Netherlands (16, 17).
These bat coronaviruses have not been cultured in vitro. The par-
tial sequence of the open reading frame 1 (ORF1) region of the
isolate from the patient from Qatar is more than 99% identical to
that of the virus reported from Saudi Arabia (HCoV-EMC) (10,
18). Previously known HCoVs are alphacoronaviruses HCoV-
229E and HCoV-NL63, betacoronavirus lineage A (HCoV-OC43
andHKU1), and betacoronavirus lineage B (SARS-CoV) (19, 20).
We have previously used ex vivo cultures of human bronchial
and lung tissues to investigate the tropismof influenza viruses (21)
and showed that productive infection of the upper airways may
correlate with pandemic potential in swine influenza viruses (22).
We now utilize ex vivo cultures of human bronchial and lung
tissue to study the tissue tropism, virus replication kinetics, apop-
tosis, and innate immune responses of HCoV-EMC infection in
comparison with those of infections with highly pathogenic
SARS-CoV and common cold-causing HCoV-229E.
As there are no specific antivirals forHCoV-EMC infection, we
explore the antiviral effects of IFNs. IFN has previously been re-
ported to inhibit SARS-CoV replication both in vitro and in ani-
mal models (23–28).
MATERIALS AND METHODS
Viruses. Human betacoronavirus of lineage C virus (HCoV-EMC) was
obtained from R. Fouchier, Erasmus MC, Rotterdam, the Netherlands,
and the virus seed stock was prepared in Vero cell culture (ATCC) in
minimal essential medium (MEM) containing 2% fetal bovine serum
(FBS) and 100 units/ml penicillin–100 g/ml streptomycin (PS). HCoV-
EMCproduced a cytopathic effect (CPE) within 1 to 2 days after infection
of Vero cells. SARS-CoV (strain HK39849) and HCoV-229E were prop-
agated in Vero cells andMRC-5 cells, respectively, as described previously
(1). Highly pathogenic avian influenza (HPAI) viruses cause severe hu-
man respiratory disease, and stocks of A/Hong Kong/483/1997 (H5N1)
virus were prepared inMDCK cells inMEMwith no FBS and with 1% PS.
All the experiments were performed in a biosafety level 3 biocontainment
facility at The University of Hong Kong.
Virus titration by TCID50 assay. Confluent 96-well tissue culture
plates of the respective cells were used for the virus titration assay for
HCoV-EMC and SARS-CoV (Vero cells), HCoV-229E (MRC-5 cells), or
influenza A H5N1 virus (MDCK cells). The cells were washed once with
phosphate-buffered saline (PBS), and the Vero and MRC-5 cells were
replenished with MEM with 2% FBS and 1% PS, while MDCK cells were
replenished withMEMwith no FBS and 1%PS. Serial half-log10 dilutions
(from 0.5 log unit to 7 log units) of virus-infected culture supernatants
were added onto the wells in quadruplicate. The plates were observed for
a CPE daily for 5 days. The viral dilution leading to a CPE in 50% of
inoculated wells was estimated by using the Karber method, designated 1
50% tissue culture infectious dose (TCID50), and used to compute the
viral titer in the test sample.
Ex vivo organ cultures and infection. Fresh biopsy specimens of hu-
man bronchus and lung parenchyma that were obtained from patients
undergoing surgical resection of lung tissue at Queen Mary Hospital as
part of clinical care but that were surplus for routine diagnostic require-
ments were used in this study. This study was approved by the Institu-
tional Review Board of The University of Hong Kong/Hospital Authority
Hong Kong West Cluster. Ex vivo cultures of human bronchial and lung
tissues were performed as previously described (21, 22, 29). The bronchial
mucosae were placed on a surgical sponge with their apical epithelial
surface facing upwards, while the lung parenchymal tissues were placed
into a 24-well plate directly with 1 ml of F12K culture medium and with
1%PS at 37°C. Bronchial and lung tissueswere infectedwithHCoV-229E,
HCoV-EMC, and SARS-CoV at a viral titer of 106 TCID50s/ml for 1 h at
37°C and washed with 5 ml of warm PBS three times to remove unbound
virus, as previously described (21, 22, 29). UV-inactivated virus and
mock-infected cells were used as controls. Culture supernatants from the
infected cultures were collected at 1, 24, 48, and 72 h postinfection (hpi)
and titrated for infectious virus using the TCID50 assay for HCoV-229E,
HCoV-EMC, and SARS-CoV, as described previously (1, 6). Increasing
virus titers over time provided evidence of productive virus replication.
Tissues were collected at 1, 24, 48, and 72 hpi for RNA extraction and at
24, 48, and 72 hpi for fixation in 10% formalin or 2.5% glutaraldehyde for
immunohistochemistry and electron microscopy, respectively.
In vitro cell culture and infection.Cells of a human alveolar epithelial
cell line (A549) were cultured using Dulbecco modified Eagle medium
with 10% FBS and 1% PS and were seeded at 1  105 cells per well in
24-well tissue culture plates. The cells were infected with HCoV-EMC,
SARS-CoV, and HPAI H5N1 virus at a multiplicity of infection (MOI) of
1. After 1 h of virus adsorption at 37°C, the virus inoculum was removed,
the cells were washedwith PBS, and the culture was replenishedwith fresh
culture medium without FBS. Evidence of viral infection and virus repli-
cation kinetics were determined by (i) assaying RNA of HCoV-EMC,
SARS-CoV, and influenza type A virus at 1, 24, and 48 hpi by quantitative
reverse transcription-PCR (RT-PCR) and (ii) titrating infectious virus in
infected culture supernatants to demonstrate productive virus replication
in Vero or MDCK cells, as appropriate.
Quantificationof viral andhost cytokine and chemokinemRNAsby
quantitative RT-PCR. Bronchial and lung tissue fragments were homog-
enized using a TissueRuptor device (Qiagen, Hilden, Germany) in 700 l
RNeasy lysis buffer with beta-mercaptoethanol on ice. A549 cell cultures
were lysed in 350 l RLT lysis buffer with beta-mercaptoethanol. RNA
extraction was carried out using an RNeasyminikit (Qiagen, Hilden, Ger-
many) following the manufacturer’s instructions with the addition of
DNase treatment, and the RNA was eluted in 50 l RNase-free water.
A one-step RT-PCR assay specific for the region upstream of the E
gene of HCoV-EMCwas adapted from a recently described protocol (18).
In brief, 5 l of purified RNA was amplified in a 25-l reaction mixture
containing 1l SSIII-Taq enzymemix (SuperScript III one-step RT-PCR
system with Platinum Taq DNA polymerase [Invitrogen]), 12.5 l of 2
reaction buffer, 0.8 mMMgSO4, 0.4 M forward primer upE-Fwd (5=-G
CAACGCGCGATTCAGTT-3=), 0.4 M reverse primer upE-Rev (5=-GC
CTCTACACGGGACCCATA-3=), and 0.2 M probe upE-Prb (5=-FAM-
CTCTTCACATAATCGCCCCGAGCTCG-TAMRA-3=, where FAM is
6-carboxyfluorescein and TAMRA is 6-carboxytetramethylrhodamine).
The reaction mixtures were first incubated at 55°C for 20 min. After a
3-min denaturation at 95°C, the reaction mixtures were then thermal
cycled for 40 cycles (94°C for 15 s, 58°C for 30 s). Total RNA harvested
fromHCoV-EMC-infected Vero cells and water were used as positive and
negative controls, respectively. The expression of the HCoV-EMC gene
was expressed as the fold change compared to its expression at 1 hpi, using
the 2CT method, where CT is the threshold cycle, as described previ-
ously (30). SARS-CoVnucleocapsid (N) protein gene expression (31) and
influenza virus matrix protein gene expression were also quantified as
previously described (31) and expressed in terms of the fold change com-
pared to the expression detected at 1 hpi.
The host gene expression profiles for proinflammatory cytokines (tu-
mor necrosis factor alpha [TNF-], IFN-, interleukin-29 [IL-29]),
chemokines (IFN--induced protein 10 [IP-10], monocyte chemotactic
protein-1 [MCP-1]), and the housekeeping (-actin) gene were detected
in absolute copy numbers determined from a standard curve generated
from a standard plasmid with a known copy number which was simulta-
neously included in the quantitative PCR (qPCR) mixture, as previously
described (21, 32). The mRNA levels of selected genes were quantified by
real-time qPCR analysis with an ABI 7500 real-time PCR system (Applied
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Biosystems). Expression of these genes was normalized by using the prod-
uct of the -actin housekeeping gene mRNA.
Generation of antisera against BtCoVHKU5Nprotein.The gene for
BtCoVHKU5N protein (GenBank accession no. EF065512) was inserted
into the Venezuelan equine encephalitis (VEE) virus replicon plasmid
pVR21 by overlap PCR, the replicon particles (VRP-HKU5 N protein)
were packaged, and titers were determined on baby hamster kidney cells
as previously described (33, 34). Five-week-old BALB/c mice (Harlan
Laboratories) were immunized with 105 infectious units (IU) of VRP-
HKU5Nprotein in a 10-l volume, and 21 days later, themice were again
boosted with the same dose of antigen. At 21 days after the boost, serum
was collected by tail nick and used in immunohistochemistry analysis.
The BtCoV HKU5 N protein shares 68% identity to the N protein of
HCoV-EMC (35), and the antiserum against the N protein was found to
cross-react with the HCoV-EMC nucleocapsid protein.
Immunohistochemistry. The 10% formalin-fixed tissues were em-
bedded in paraffin and stained using a polyclonal mouse antibody raised
against coronavirus HKU5 N glycoprotein (1:200), which cross-reacts
with HCoV-EMC by Western blotting and immunofluorescence assays;
mouse monoclonal antibody against SARS-CoV nucleoprotein, which is
reactive with SARS-CoV at a 1:50 dilution, as previously described (8);
mouse monoclonal antibody 1E7, which is reactive with HCoV-229E at a
1:100 dilution (provided by Lia van der Hoek); and cleaved caspase 3
(CST-9661S; Cell Signaling) as amarker of apoptotic cells. The reaction of
the primary antibody was revealed by the use of biotinylated goat anti-
mouse antibody (1:500; 115-065-146; Jackson) and developed using a
NovaRed substrate kit (SK-4800; Vector Labs). Antibodies to CD68 for
macrophages, AE1/AE3 for epithelial cells, -tubulin (F-2043; Sigma) for
ciliated bronchial epithelial cells, MUC5AC (18-2261; Life Technology)
for goblet cells, and podoplanin for type I pneumocytes were used for
double labeling using immunofluorescencewith secondary antibody con-
jugated with fluorescein isothiocyanate (FITC). HCoV-EMC was de-
tected usingHKU5Nprotein antiserumandVector Red substrate in these
double-labeling experiments, as this substrate is also fluorescent when
using a tetramethyl rhodamine isocyanate filter. The stained preparations
were examined using a Nikon Ni immunofluorescence microscope, and
images were captured using a SPOT Slider 2-megapixel camera. Double-
chromogen immunohistochemistry for caspase 3 was performed by first
detecting the viral antigen using an alkaline phosphatase-conjugated
streptavidin technique, followed by the use of ImmPRESS horseradish
peroxidase (MP-7401; Vector Labs) for detection of the cleaved caspase 3
(9661S; Cell Signaling).
Transmission electron microscopy. Bronchial and lung tissues were
fixed in 2.5% glutaraldehyde, washed three times in PBS, and serially
dehydrated. The tissues were postfixed in 1% osmium tetroxide and em-
bedded in Araldite resin (Polysciences, Inc., Warrington, PA). Sections
were examined with a transmission electron microscope (CM100;
Philips).
Antiviral effect of interferon treatment in ex vivo human lung tis-
sue. Recombinant IFN- (PHC4014; Invitrogen) and IFN- (PHC4244;
Invitrogen) were reconstituted into 1,000 U/ml of F12Kmediumwith 1%
PS. Preinfection and postinfection administration regimes were applied.
For the preinfection IFN treatment, lung tissue fragments were pretreated
with either IFN- or IFN- 24 h prior to infection. The lung tissue frag-
ments preincubated with IFN were then infected with HCoV-EMC or
SARS-CoV as described above, and the infected culture was replenished
with culture medium with the corresponding IFN after infection. For the
postinfection treatment, untreated lung tissue fragments were infected,
and at 1 hpi, the infected culturewas replenishedwithmediumcontaining
1,000 U/ml of IFN. Control lung tissue cultures without any IFN were
used for comparison. Supernatants from the infected lung tissue explant
cultures were collected at 1, 24, 48, and 72 hpi and titrated for infectious
virus using the TCID50 assay.
Statistical analysis. Experiments were performed independently with
specimens from at least three different donors in duplicate. Results shows
in the figures are the calculated mean and standard error of the mean.
Mock-infected tissue served as a negative control. The differences in the
log10-transformed viral titers among different viruses at different time
points postinfection and differences in the amounts of cytokine and
chemokinemRNAs of coronavirus-infected cells were compared by using
one-way analysis of variance, followed by a Bonferroni multiple-compar-
ison test. Differences were considered significant at a P value of 0.05.
The statistical analysis was performed using GraphPad Prism (version 5)
software.
RESULTS
Infection and replication of HCoV-EMC, SARS-CoV, and
HCoV 229E in ex vivo cultures of human bronchial and lung
tissue. In ex vivo cultures of human bronchial tissue, HCoV-EMC
infected the tissue and productively replicated, with a 2-log-unit
increase in viral titer from 1 hpi to 72 hpi (P 0.005) (Fig. 1B and
D). SARS-CoV infected bronchial tissue (Fig. 1C) and showed a
less than 1-log-unit increase in titer from 1 hpi to 24 hpi, but the
increase did not reach statistical significance (Fig. 1D). HCoV-
229E did not detectably infect or replicate in bronchial tissues
(Fig. 1A and D). In ex vivo cultures of human lung tissue, viral
antigen was not detected in HCoV-229E-inoculated tissues (Fig.
1E), and no productive replication was observed (Fig. 1H), indi-
cating that HCoV-229E does not replicate in the human lung.
Both HCoV-EMC (Fig. 1F) and SARS-CoV (Fig. 1G) extensively
infected and replicated in (Fig. 1H) the lung parenchymal tissues,
as shown by the presence of viral antigen in these tissues along
with an approximately 2-log-unit increase in HCoV-EMC and
SARS-CoV loads from 1 hpi to 48 hpi.
HCoV-EMC cell tropism in the human respiratory tract. In
order to identify the target cells of HCoV-EMC in the human
respiratory tract, we performed costaining ofHCoV-EMCantigen
(stained in red) with specific cell markers (stained in green) in
HCoV-EMC-infected human bronchial and lung tissues in ex vivo
culture (Fig. 2). In bronchial tissues, we stained the ciliated cells
(Fig. 2A) and goblet cells (Fig. 2B) using-tubulin andMUC5AC,
respectively. The infected cells (in red) were not colocalized with
these two major cell types in the bronchus, and viral antigen was
mainly found in nonciliated bronchial epithelial cells.
In lung, macrophages, epithelial cells, and type I pneumocytes
were stained with the specific markers CD68 (Fig. 2C), AE1/AE3
(Fig. 2D), and podoplanin (Fig. 2E), respectively.HCoV-EMCdid
not costain with macrophages (Fig. 2C), but there was overlap-
ping of staining with the AE1/AE3 marker (Fig. 2D), which sug-
gested that the principal target cells of HCoV-EMC infection were
of epithelial origin, and focal colocalization was found in type I
pneumocytes (Fig. 2E).
Cellular morphology and immunohistochemistry for viral an-
tigen (nucleoprotein) in the HCoV-EMC-infected lung tissues
(Fig. 1F) gave additional information on cell types targeted by
HCoV-EMC at 48 hpi. Endothelial cells within the medium-size
interstitial vessels of the lung (Fig. 2F) and the bronchiolar epithe-
lial cells (Fig. 2G) were found to stain positive for the nucleopro-
tein of HCoV-EMC. The tropism of HCoV-EMC in lung endo-
thelial cells may suggest the possibility of extrapulmonary
dissemination.
Electron microscopy shows budding HCoV-EMC virions in
bronchial and alveolar epithelial cells. To further confirm the
sites of HCoV-EMC replicationwithin the human lung, transmis-
sion electron microscopy of the ex vivo-infected bronchial and
lung parenchymal tissues was performed. Virion-containing cells
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in the bronchus were flattened nonciliated bronchiolar-type epi-
thelial cells (Fig. 3A), and those in the lung were type II pneumo-
cytes with visible lamellar bodies (Fig. 3C). While virions were
identified intracellularly, large aggregates of virions in intracyto-
plasmic secretory vesicles were not conspicuous. Ultrastructural
examination of the bronchus and lung showed enveloped viral
particles from75 to 85 nm in diameter (Fig. 3B andD). Thesewere
often associated with a rim of spikes or coronameasuring approx-
imately 8 nm in length.
Extensive apoptosis in HCoV-EMC-infected human lung
tissue ex vivo cultures. By immunohistochemistry, we found
extensive expression of cleaved caspase 3, an apoptosis marker,
in ex vivo lung tissue infected with HCoV-EMC (Fig. 4B) and
SARS-CoV (Fig. 4C) but not in mock-infected (Fig. 4A) human
lung tissue. In order to investigate if the apoptosis was induced
directly by coronavirus infection in the human lung, we per-
formed costaining by immunohistochemistry of HCoV-EMC
antigen (stained in pink) with cleaved caspase 3 (stained in
reddish brown) using HCoV-EMC-infected (Fig. 4D) and
SARS-CoV-infected (Fig. 4E) human lung tissues in ex vivo
culture. Examination of both HCoV-EMC- and SARS-CoV-
infected lung tissue revealed that the apoptotic cells were not
the viral protein-expressing cells (Fig. 4D and E), suggesting
that paracrine mechanisms may contribute to induction of
apoptosis.
Viral and host gene expression upon HCoV-EMC infection
in ex vivo cultures of bronchial and lung tissue and in vitro
culture of A549 cells. Ex vivo bronchial and lung tissues from
three donors were infected with HCoV-EMC and RNA was ex-
tracted from infected cells at 1, 24, 48, and 72 hpi. Viral RNA was
quantitated by RT-PCR. Host expression of mRNA for type I
(IFN-) and type III (IL-29) interferons and proinflammatory
cytokines and chemokines TNF- and IP-10 was quantitated in
HCoV-EMC- or mock-infected bronchial and lung tissues. Viral
gene expression increased by more than 2,000-fold in bronchial
tissue cultures andmore than 180-fold in lung tissue cultures, with
one donor showing an exceptional 6,000-fold increase in a lung
tissue culture (Fig. 5A). However, compared to mock-infected
cultures, HCoV-EMC infection in bronchial and lung tissues
failed to induce IFN- or TNF- (Fig. 5B and D). There was
marginal induction of IL-29 in virus-infected lung tissue cultures
at 48 hpi (P 0.05) compared with that for mock-infected tissue
(Fig. 5C) and higher IP-10 mRNA expression at 24 hpi compared
with that for mock-infected bronchial tissue (P 0.05) (Fig. 5E).
IL-1, MCP-1, and RANTES mRNAs were also similarly quanti-
fied, with no upregulation of these genes detected in bronchial or
lung tissues infected with HCoV-EMC (data not shown). Inacti-
vation of the HCoV-EMC by UV irradiation prior to infection of
ex vivo bronchial and lung tissue cultures completely abolished
viral replication and any cytokine induction (data not shown).
FIG 1 Tissue tropism of HCoV-EMC in human bronchus and lung. Bronchial (A to C) and lung (E to G) tissues were infected with HCoV-229E, HCoV-EMC,
and SARS-CoV. At 24 hpi, the tissues were fixed and tissue sections were stained for human coronavirusN protein (reddish brown), as described inMaterials and
Methods. Viral replication kinetics in ex vivo cultures of bronchial (D) and lung (H) biopsy tissue specimens infected with 106 TCID50s/ml of coronaviruses were
determined by virus titration at 37°C. The bar charts show the mean and the standard error of the mean of the virus titer pooled from at least three independent
experiments. Asterisks indicate a statistically significant increase in viral yield compared to that at 1 hpi: *, P 0.05; **, P 0.005; ***, P 0.0005.
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In order to confirm the apparent lack of host IFN responses
elicited by HCoV-EMC in the ex vivo bronchial and lung tissue
cultures, we carried out further experiments quantitating viral
RNA and host type I and III IFN, TNF-, and IP-10mRNA in cells
of the alveolar epithelial cell line A549 infected with HCoV-EMC,
SARS-CoV (nonreplicating negative control), and HPAI H5N1
virus (high cytokine-inducing positive control) or uninfected
A549 cells (control). We demonstrated by TCID50 assay and viral
gene expression that HCoV-EMC and HPAI H5N1 virus repli-
cated in A549 cells, while SARS-CoV showed no evidence of rep-
lication (Fig. 6A and B). While influenza A H5N1 virus strongly
induced IFN- (Fig. 6C), TNF- (Fig. 6D), and IP-10 (Fig. 6E)
gene expression, none of these cytokines were induced by HCoV-
EMC infection of A549 cells.
IFNs inhibit HCoV-EMC replication in ex vivo lung tissue
cultures. HCoV-EMC and SARS-CoV productively replicated in
ex vivo lung tissue cultures (Fig. 1H). Using this ex vivo lung tissue
culture model, we investigated the effect of IFN- or IFN- treat-
ment commencing 1 h after infection on viral replication. A sig-
nificant decrease in the replication kinetics of HCoV-EMC was
observed, with an approximately 2-log-unit decrease in infectious
viral titers being observed at 48 hpi and 72 hpi (Fig. 7A). This
decrease paralleled a reduction in viral gene copy load assayed by
quantitative RT-PCR assays (data not shown). IFN- or IFN-
treatment also inhibited SARS-CoV replication in ex vivo lung
tissue cultures, but the effect was less pronounced than that with
HCoV-EMC infection (Fig. 7B). In addition, the effect of IFN-
or IFN- treatment 24 h prior to infection continued into the
postinfection period was also examined. This treatment did not
further enhance the antiviral effect on HCoV-EMC replication
(data not shown).
DISCUSSION
We compared the tropism of the novel human coronavirus EMC,
SARS-CoV, and HCoV-229E on ex vivo cultures of human lung
and bronchial tissue using immunohistochemistry to indicate in-
fection and by quantitating infectious viral titers from 1 to 72 hpi
to indicate productive viral replication. HCoV-EMC and SARS-
CoV infected and productively replicated in ex vivo cultures of
human lung. While both viruses also infected bronchial epithelial
cells, as assessed by immunohistochemistry, there was no signifi-
cant increase in infectious viral titers of SARS-CoV in the bron-
chial tissue ex vivo cultures, while HCoV-EMC demonstrated ev-
idence of productive replication.
Human infections associated with HCoV-EMC have so far ap-
peared to be relatively severe clinically, but it is unclear whether
this severity reflects an ascertainment bias where milder disease
goes unrecognized. Future studies, including seroepidemiological
investigations, are needed to establish the true severity of this in-
fection in human populations. The tropism and replication com-
petence of HCoV-EMC in human lung and bronchus demon-
strated here suggest that HCoV-EMC replicates at least as well as
or even better than SARS-CoV in human lung and bronchial tis-
sues and targets type I and type II alveolar epithelial cells, high-
lighting the potential threat posed by this novel virus. Type II
alveolar epithelial cells are crucial in the regeneration of the alve-
olar epithelium following injury by infection, and a virus that
targets this cell type is likely to lead to significant lung pathology.
Previous studies have shown that HPAI H5N1 virus, one that is
also known to cause severe primary viral pneumonia and acute
respiratory distress syndrome, also replicates efficiently in the al-
veolar epitheliumof ex vivo lung tissue cultures (29). In agreement
FIG 2 Cellular localization of HCoV-EMC in lung tissue. HCoV-EMC was stained with Vector Red (red) and cell markers conjugated with FITC (green) for
detection of -tubulin (ciliated cell marker) (A) and MUC5AC (goblet cell marker) (B) in bronchial tissue and CD68 (macrophage marker) (C), AE1/AE3
(epithelial cellmarker) (D), and podoplanin (type I pneumocytemarker) (E) in lung tissue at 24 hpi.White arrows in panels D and E denote cells with costaining.
(F) Cellular tropism of HCoV-EMC in lung tissue. Human coronavirus N protein (stained in reddish brown and marked with red arrows) was identified in
endothelial cells at 24 hpi. (G) Bronchiolar epithelial cells at 48 hpi.
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with the milder clinical disease caused by HCoV-229E, HCoV-
229E failed to infect or replicate in either bronchial or lung tissues.
However, it is relevant to note that not all viruses that can
replicate in the alveolar epithelium of the ex vivo cultures of
lung tissue are consistently associated with severe respiratory
disease (e.g., the 2009 pandemic H1N1 virus) (21). Thus, the
capacity for replication in alveolar epithelium in ex vivo cul-
tures of lung tissue appears to be a necessary but not sufficient
correlate of disease severity.
In previous studies with swine influenza viruses, we found that
a lack of tropism for ex vivo cultures of bronchial and nasopha-
ryngeal tissue correlated with a lack of transmission in humans
(22). HCoV-229E, which is known to transmit efficiently in hu-
mans, also failed to replicate efficiently in ex vivo bronchial tissue
cultures, although HCoV-229E infection and replication were
demonstrated in in vitro cultures of a pseudostratified human air-
way epithelial cell model (36) and well-differentiated normal hu-
man bronchial epithelial cells (6). Coronaviruses causing the
common cold have been shown to infect the nasal mucosa of
humans (37) andwould presumably replicate in ex vivo cultures of
human nasopharyngeal or tonsil tissue. Since human nasopha-
ryngeal tissue for ex vivo culture is less readily available, we have
not so far obtained data from cultures infected with HCoV-229E,
SARS-CoV, or HCoV-EMC. More systematic investigations of
HCoV-EMC in ex vivo nasopharyngeal tissue cultures would pro-
vide further information on the tropism of this virus for the upper
respiratory tract, providing insights into potential human trans-
missibility or a lack thereof.
Immunohistochemical analysis of virus-infected ex vivo lung
tissue cultures also demonstrated that endothelial cells withinme-
dium-size interstitial blood vessels of the lung were also targets for
HCoV-EMC infection. This may imply that the virus, as with
SARS-CoV, may spread systemically to affect distant organs.
Thus, the renal dysfunction that was repeatedly seen in patients
infected with HCoV-EMC may possibly be due to virus dissemi-
nation to the kidney, although there is no direct evidence of this at
present. Further clinical studies are needed to address whether
viral dissemination does in fact occur and whether the renal dys-
function is due to viral invasion of the kidneys.
Immunofluorescence study and transmission electronmicros-
copy of infected ex vivo cultures of lung and bronchial tissue al-
lowed us to further define the cell types targeted by HCoV-EMC.
Nonciliated bronchial epithelial cells, bronchiolar epithelial cells,
and type I and type II pneumocytes appear to be the major targets
for HCoV-EMC infection. We did not observe virus-infected al-
veolar macrophages in ex vivo lung tissue cultures under these
experimental conditions. A preliminary study of human periph-
eral bloodmonocyte-derivedmacrophages also showed that these
cells did not support the replication of HCoV-EMC (unpublished
data).
Mechanisms that contribute to the pathogenesis of respiratory
viruses such as SARS-CoV and avian influenza A H5N1 virus in-
FIG 3 Transmission electron microscopy locating the budding site of HCoV-EMC in the human bronchus and lung. Budding of virions from bronchial
epithelial cells (A, B) and alveolar epithelial cells (C, D) at 48 hpi. Black arrows, type II alveolar epithelial cells with lamellar bodies.
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clude direct virus replication-induced cell apoptosis, necrosis, or
autophagy; bystander apoptosis; or dysregulation of host innate
inflammatory responses. We found extensive apoptosis in SARS-
CoV- andHCoV-EMC-infected ex vivo lung tissues which did not
colocalize with viral antigen, suggesting that both viruses can in-
duce apoptosis via paracrine mechanisms. Unlike influenza A
H5N1 virus, which induces a prominent proinflammatory cyto-
kine response, and SARS-CoV, which induces a dysregulated cy-
tokine responses (i.e., poor IFN response but potent proinflam-
matory chemokine responses), HCoV-EMC infection elicited
poor proinflammatory chemokine and cytokine responses, in-
cluding poor type I and III IFN responses both in ex vivo lung
FIG 4 Apoptotic cells identified in human lung tissue ex vivo culture upon HCoV-EMC and SARS-CoV infection. (A to C) Ex vivo culture of lung tissue mock
infected (A) or infected with HCoV-EMC (B) or SARS-CoV (C) at 48 hpi. The reddish brown stain identifies the presence of cleaved caspase 3. (D and E)
Costaining of HCoV-EMC (D) and SARS-CoV (E) antigen (pink stain) with cleaved caspase 3 (reddish brown stain).
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tissue cultures and in the alveolar epithelial cell line A549. Thus,
immunomodulatory therapies that have been investigated in ex-
perimental models of H5N1 disease (38–40) may have no clinical
utility in HCoV-EMC infection. On the other hand, IFN therapy
may be of potential benefit. SARS-CoV did not appear to induce
IFN responses, although other proinflammatory cytokines were
potently induced (1), and it was found that a number of SARS-
CoV proteins functioned as IFN antagonists in vitro (41). IFN
FIG 5 Human HCoV-EMC gene expression and the major cytokine and chemokine expression in bronchial and lung tissues in response to infection. (A)
Expression ofHCoV-EMC genes expressed as the fold change at 24, 48, and 72 hpi comparedwith that at 1 hpi. Gray bars, data from ex vivo bronchial tissue from
three donors; black bars, data from ex vivo lung tissue from three donors. (B to E) IFN- (B), IL-29 (C), TNF- (D), and IP-10 (E) expression frommock-infected
and infected ex vivo cultures at 1, 24, 48, and 72 hpi. The graph shows the mean and standard error of mean numbers of copies of mRNA per 105 -actin copies
from three representative experiments. *, P 0.05.
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therapy has been shown to have therapeutic potential in SARS-
CoV infections using in vitro (42) and nonhuman primate (24)
models, and some trend toward clinical benefit was observed in
human studies that were based on retrospective controls rather
than in randomized controlled clinical trials (43). Ex vivo cultures
of human lung tissue have been used to demonstrate the thera-
peutic benefits of IFNs in HPAI H5N1 virus infections (44).
Therefore, we explored the antiviral effects of IFNs on HCoV-
EMC infection in a human ex vivo lung tissue culture model.
Both IFN- and IFN- significantly suppressed viral replica-
tion when added to ex vivo cultures of human lung tissue 1 h after
HCoV-EMC infection. IFN treatment of the cells that began 24 h
prior to infection and continued into the postinfection period did
not enhance the antiviral effect on HCoV-EMC replication. As
there are currently no antivirals for treatment of HCoV-EMC,
these findings provide a therapeutic option for this serious disease.
Further studies using relevant animal models would be a priority
to confirm the utility of IFNs as therapeutic and/or prophylactic
interventions for HCoV-EMC infection. The biological basis for
innate immune evasion by HCoV-EMC deserves investigation.
A recent study (published online after the submission of our
manuscript) has reported that HCoV-EMC replicates more effi-
ciently than SARS-CoV in a pseudostratified culture of human
airway epithelium (HAE) that morphologically and functionally
resembles human upper conducting airways in vitro (36). Their
FIG 6 Viral replication and cytokine and chemokine expression of HCoV-EMC in A549 cells. (A) A549 cells infected with HCoV-EMC, SARS-CoV, and
influenza H5N1 virus (MOI, 1). Viral replication was determined by TCID50 assay. The bar chart shows the mean and the standard error of mean titer of
virus pooled from three independent experiments. Asterisks indicate a statistically significant increase in viral yield compared to that at 1 hpi: **, P 0.05;
***, P 0.0005. (B) Expression of HCoV-EMC, SARS-CoV, and influenza H5N1 virus genes expressed as the fold change compared with that at 1 hpi. (C
to E) IFN- (C), TNF- (D), and IP-10 (E) gene expression frommock-infected and HCoV-EMC-, SARS-CoV-, and influenza H5N1 virus-infected A549
cells at 1, 24, and 48 hpi. The graph shows the mean and standard error of the mean numbers of copies of mRNA per 105 -actin copies from three
representative experiments.
FIG 7 Interferon treatments suppressed HCoV-EMC and SARS CoV rep-
lication in human lung ex vivo culture. The human lung ex vivo cultures
were infected with 106 TCID50s/ml of HCoV-EMC or SARS-CoV for 1 h at
37°C. A control culture consisting of F12Kmedium plus 1% PS (black bars)
or culture medium with IFN- (white bars) or IFN- (gray bars) at a
concentration of 1,000 U/ml in F12K medium plus 1% PS was used to
replenish the medium at 1 hpi. Supernatants were collected from infected
cultures at 1, 24, 48, and 72 hpi and titrated in Vero cells. Replication
kinetics of HCoV-EMC (A) and SARS-CoV (B) were plotted to show the
inhibitory effect of IFNs on virus replication posttreatment. *, a statistically
significant difference (P  0.05) at the same time point between control
and IFN treatments.
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data pertained only to the bronchial region of the respiratory tract,
and furthermore, the extent of HCoV-EMC replication in that in
vitro HAE model was more limited than what we observed in the
ex vivo bronchial or lung tissue cultures. As with our results, they
showed that HCoV-EMC is a weak inducer of IFNs and that IFNs
can inhibit replication of HCoV-EMC in HAE cultures (36). Our
results support and extend those observations using human bron-
chial tissue cultured ex vivo, add information on the tropism of
HCoV-EMC in ex vivo lung and bronchial tissue infection, and
demonstrate the effect of interferon on human tissues infected
with this virus.
In conclusion, this study illustrates the clinical utility of using
ex vivo cultures of the human respiratory system to investigate
newly emerging respiratory viruses. There have so far been no
autopsy reports describing the virus-induced pathology in the
lung, and such studies will complement and confirm the data that
we report here. It must be noted that autopsy data, even when
available, often reflect the late-stage disease in patients who may
have been kept alive onmechanical ventilation for long periods of
time. Thus, studies with ex vivo experimental infection of the hu-
man respiratory tract are invaluable to understand virus tropism
and pathogenesis as well as to evaluate potential therapeutic op-
tions.
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